May 15, 2018 06:33 AM EDT

Polyphor parlays a pathogen-specific antibiotic and I/O work into a $165M IPO for its PhIII program

John Carroll

Editor & Founder

Polyphor has successfully completed an IPO, raising about $165 million to back its Phase III development of a new antibiotic specifically designed to counterattack against …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Polyphor parlays a pathogen-specific antibiotic and I/O work into a $165M IPO for its PhIII program

John Carroll

Editor & Founder

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

'Go ahead and do it': Top RFK Jr. deputy dares drugmakers that might pull manufacturing over new price pressure

The inside story of the six-month sprint to create the first custom CRISPR therapy for one infant’s rare disease

New CBER chief Prasad is readying 'massive framework' around vaccines, Makary says

Eli Lilly turns to South Korean RNA editing biotech for hearing loss in deal worth $1.3B

Bristol Myers CEO says America’s biopharma pole position is not guaranteed

Exclusive: Drug compounder Empower was built on risky shortcuts, ex-employees and inspections allege

Polyphor par­lays a pathogen-spe­cif­ic an­tibi­ot­ic and I/O work in­to a $165M IPO for its PhI­II pro­gram

Editor & Founder

Sign up to read this article for free.

more like this

Celldex Therapeutics

Hampton, NJ, USA

Polyphor parlays a pathogen-specific antibiotic and I/O work into a $165M IPO for its PhIII program